SCHEMBL23926335

SCHEMBL23926335

Cc1ccc(O)c(-c2nc(-c3cccnc3O)c3n2CCCC3)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
CYP19A1 P11511 1/20 0.37
RORC P51449 6/20 0.35
TP53 P04637 3/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
COMT P21964 3/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPK1 P28482 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
PTAFR P25105 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118951 1.00 ADORA3 (0.38) ADORA3ADORA2ACYP19A1RORCTP53
SCHEMBL30118958 0.88 CYP2C19 (0.37) ADORA3ADORA2ACYP19A1RORCTP53
SCHEMBL30118905 0.88 HPGD (0.41) ADORA3ADORA2ARORCTP53MAPT
SCHEMBL23926363 0.88 CYP2C19 (0.37) ADORA3ADORA2ACYP19A1RORCTP53
SCHEMBL23926329 0.88 HPGD (0.41) ADORA3ADORA2ARORCTP53MAPT
SCHEMBL23926361 0.80 ALDH1A1 (0.37) ADORA3ADORA2ARORCTP53MAPT
SCHEMBL30118892 0.80 ALDH1A1 (0.37) ADORA3ADORA2ARORCTP53MAPT
SCHEMBL23926334 0.79 RORC (0.40) RORC
SCHEMBL23926383 0.76 HPGD (0.41) RORCTP53MAPTKDM4EALDH1A1
SCHEMBL23926385 0.74 ADORA3 (0.39) ADORA3ADORA2ACYP19A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 ADORA3 2126/4885ADORA2A 1675/4885CYP19A1 1738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.